Immunotherapy milestone in the maintenance setting: #FDA Approves the PD-L1 inhibitor #Bavencio (avelumab) as frontline maintenance in metastatic bladder cancer (urothelial carcinoma) $PFE $MRK https://t.co/ldnfeUinHS via @onclive